Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058353 | 0.82 | ACHE (0.33) | CYP2A6GRM4CHRNA7 | |
| SCHEMBL15928098 | 0.81 | ROCK1 (0.44) | NOS3NOS1NOS2 | |
| SCHEMBL19155639 | 0.78 | PDE3A (0.36) | GRM4PDE3BPDE3A | |
| SCHEMBL10078326 | 0.77 | CYP2A6 (0.50) | CYP2A6PDE3BPDE3A | |
| SCHEMBL24659178 | 0.75 | CYP1A2 (0.44) | CYP2A6GRM4 | |
| SCHEMBL19044339 | 0.74 | CYP2A6 (0.47) | CYP2A6PDE3BPDE3A | |
| SCHEMBL10057582 | 0.73 | CYP2A6 (0.50) | CYP2A6PDE3BPDE3A | |
| SCHEMBL16674963 | 0.71 | LMNA (0.38) | GRM4 | |
| SCHEMBL27439680 | 0.71 | CHRNB2 (0.36) | GRM4NOS3NOS1NOS2 | |
| SCHEMBL27251652 | 0.71 | CYP2A6 (0.44) | CYP2A6PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | CYP2A6 1807/4885GRM4 4728/4885CHRNA7 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.